Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 1155Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
OPINION
Year : 2022  |  Volume : 13  |  Issue : 3  |  Page : 129-131

Need for revision: EC process, members' training, and compensation formula in the New Drugs and Clinical Trials Rules 2019


Scientia Clinical Services, Pune, Maharashtra, India

Correspondence Address:
Dr. Ravindra Bhaskar Ghooi
E 516, The Island, Wakad, Pune - 411 057, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/picr.picr_251_21

Rights and Permissions

The New Drugs and Clinical Trial Rules (NDCTR) came in force in 2019, these brought in some changes, but certain earlier parts, such as Rule 122 DAB, were incorporated unchanged. A few sections of the NDCTR are problematic and need revision for the smooth conduct of clinical trials in India. Training of Ethics Committee (EC) members and other stakeholders is a very important driver for clinical research but has not been defined clearly. In addition, some processes of EC review need a relook. Compensation formulae were finalized in 2013; now, the altered economic situation has eroded the value of money. Hence, for the protection of research participants, an urgent review of the compensation formula is suggested.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3221    
    Printed60    
    Emailed0    
    PDF Downloaded509    
    Comments [Add]    

Recommend this journal